Researchers from China Pharmaceutical University have recently reported the discovery and preclinical characterization of a series of novel dihydroquinolin-4(1H)-one derivatives targeting the colchicine-binding site and intended for use as antitumor agents.
Researchers from Fudan University and affiliated organizations have reported the discovery of dual inhibitors of histone deacetylase (HDAC) and tubulin polymerization as potential anticancer agents.
Microtubule-targeting agents impact microtubule dynamics to induce mitotic arrest and tumor cell death. Tubulin is therefore a relevant target for the discovery of new agents acting as tumor neovasculature disruptors. Researchers from Nanjing Keygen Biotech Co. Ltd. have reported on the design and optimization of novel tubulin polymerization inhibitors with antiangiogenesis activity that led to the identification of [I] as the compound.
Humanwell Healthcare (Group) Co. Ltd. has described new dual microtubule destabilizers (tubulin polymerization inhibitors) and proto-oncogene tyrosine-protein kinase Src inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, actinic keratosis, vitiligo and systemic lupus erythematosus, among others.
Researchers from Shenyang Pharmaceutical University and affiliated organizations presented the discovery of novel tubulin polymerization inhibitors as potential anticancer drug candidates.
